News | February 03, 2026
Artemis Medicare reports strong Q3 growth: revenue up 17%, net profit up 8%
Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh
Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
Subscribe To Our Newsletter & Stay Updated
